Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Cancer Res. 2013 Jun 17;73(15):4801–4809. doi: 10.1158/0008-5472.CAN-12-3273

Table 2.

Serum miRNA expression associated with 2-year survival in patients with advanced NSCLC from the study population recruited at the University of Texas MD Anderson Cancer Center between 2002 and 2009.

Expression levela Training set Testing set Combined set

2-year survival 2-year survival 2-year survival



N (No) N (Yes) Adjusted HRb
(95% CI)
P MST N (No) N (Yes) Adjusted HRb
(95% CI)
P MST N (No) N (Yes) Adjusted HRb
(95% CI)
P MST
n% n% n% n% n% n%
miR-16 <0.71 83(97.7) 2(2.4) 1(reference) 7.9 88(98.9) 1(1.1) 1(reference) 9.0 171(98.3) 3(1.7) 1(reference) 8.5
>0.71 51(60.7) 33(39.3) 0.44(0.29–0.68) 1.9×10−04 16.7 54(63.5) 31(36.5) 0.37(0.25–0.55) 1.3×10−06 19.0 105(62.1) 64(37.9) 0.39(0.29–0.52) 1.7×10−10 18.0

miR-30e-3p <0.58 86(100) 0(0) 1(reference) 8.3 89(98.9) 1(1.1) 1(reference) 9.2 175(99.4) 1(0.6) 1(reference) 8.7
>0.58 48(56.5) 37(43.5) 0.45(0.29–0.69) 3.1×10−04 20.4 54(62.8) 32(37.2) 0.38(0.25–0.58) 5.6×10−06 19.0 102(59.7) 69(40.4) 0.4(0.30–0.54) 7.8×10−10 19.8

miR-106a <0.68 80(92.0) 7(8.1) 1(reference) 7.6 83(98.8) 1(1.2) 1(reference) 8.6 163(95.3) 8(4.7) 1(reference) 8.5
>0.68 56(64.4) 31(35.6) 0.57(0.39–0.85) 5.7×10−03 15.7 60(65.2) 32(34.8) 0.40(0.28–0.59) 2.8×10−06 16.0 116(64.8) 63(35.2) 0.47(0.36–0.61) 2.0×10−08 16.0

miR-148b <0.72 78(96.3) 3(3.7) 1(reference) 7.8 78(96.3) 3(3.7) 1(reference) 8.8 156(96.3) 6(3.7) 1(reference) 8.3
>0.72 51(63.0) 30(37.0) 0.49(0.33–0.74) 5.9×10−04 16.4 57(67.1) 28(32.9) 0.51(0.35–0.75) 5.3×10−04 14.4 108(65.1) 58(34.9) 0.5(0.38–0.65) 3.4×10−07 15.5

miR-26a <0.68 78(89.7) 9(10.3) 1(reference) 8.5 77(96.3) 3(3.8) 1(reference) 9.0 155(92.8) 12(7.2) 1(reference) 8.7
>0.68 57(66.3) 29(33.7) 0.65(0.44–0.95) 2.8×10−02 15.7 65(68.4) 30(31.6) 0.45(0.30–0.66) 5.8×10−05 15.5 122(67.4) 59(32.6) 0.51(0.39–0.67) 7.5×10−07 15.7

miR-27a <0.67 81(93.1) 6(6.9) 1(reference) 8.6 79(97.5) 2(2.5) 1(reference) 9.0 160(95.2) 8(4.8) 1(reference) 8.7
>0.67 55(64.0) 31(36.1) 0.59(0.4–0.87) 7.3×10−03 16.4 64(67.4) 31(32.6) 0.47(0.32–0.71) 2.3×10−04 16.0 119(65.8) 62(34.3) 0.51(0.39–0.67) 9.3×10−07 16.2

miR-106b <0.70 81(93.1) 6(6.9) 1(reference) 7.2 85(95.5) 4(4.5) 1(reference) 8.9 166(94.3) 10(5.7) 1(reference) 8.3
>0.70 55(64.0) 31(36.1) 0.52(0.35–0.77) 1.1×10−03 16.4 58(66.7) 29(33.3) 0.5(0.34–0.72) 2.8×10−04 15.5 113(65.3) 60(34.7) 0.53(0.41–0.68) 9.4×10−07 16.0

miR-301a <1.16 71(92.2) 6(7.8) 1(reference) 7.6 73(93.6) 5(6.4) 1(reference) 8.3 144(92.9) 11(7.1) 1(reference) 7.9
>1.16 50(65.8) 26(34.2) 0.53(0.36–0.8) 2.1×10−03 14.4 51(66.2) 26(33.8) 0.54(0.35–0.82) 3.7×10−03 16.0 101(66.0) 52(34.0) 0.53(0.40–0.70) 6.7×10−06 15.8

miR-27b <0.72 79(91.9) 7(8.1) 1(reference) 7.1 75(93.8) 5(6.3) 1(reference) 9.0 154(92.8) 12(7.2) 1(reference) 8.2
>0.72 56(65.9) 29(34.1) 0.53(0.36–0.79) 1.6×10−03 14.8 66(74.2) 23(25.8) 0.66(0.46–0.93) 1.9×10−02 11.1 122(70.1) 52(29.9) 0.58(0.45–0.75) 2.2×10−05 13.2

miR-152 <0.68 77(91.7) 7(8.3) 1(reference) 7.8 82(92.1) 7(7.9) 1(reference) 8.6 159(91.9) 14(8.1) 1(reference) 8.4
>0.68 55(66.3) 28(33.7) 0.6(0.41–0.87) 7.2×10−03 14.4 56(70) 24(30.0) 0.60(0.42–0.86) 5.3×10−03 12.7 111(68.1) 52(31.9) 0.59(0.46–0.75) 3.3×10−05 14.1

miR-20a <0.67 79(92.9) 6(7.1) 1(reference) 7.8 76(92.7) 6(7.3) 1(reference) 9.0 155(92.8) 12(7.2) 1(reference) 8.5
>0.67 55(65.5) 29(34.5) 0.63(0.42–0.95) 2.7×10−02 14.3 66(71.0) 27(29.0) 0.58(0.41–0.83) 2.5×10−03 12.9 121(68.4) 56(31.6) 0.62(0.48–0.79) 1.5×10−04 14.1

miR-30a-5p <0.61 75(89.3) 9(10.7) 1(reference) 8.7 76(90.5) 8(9.5) 1(reference) 8.6 151(89.9) 17(10.1) 1(reference) 8.7
>0.61 55(65.5) 29(34.5) 0.69(0.48–1.01) 5.5×10−02 9.6 66(72.5) 25(27.5) 0.58(0.41–0.83) 2.6×10−03 11.6 121(69.1) 54(30.9) 0.63(0.49–0.81) 3.2×10−04 11.5

miR-148a <0.74 79(92.9) 6(7.1) 1(reference) 8.2 80(90.9) 8(9.1) 1(reference) 9.6 159(91.9) 14(8.1) 1(reference) 8.8
>0.74 55(64.7) 30(35.3) 0.57(0.39–0.84) 3.8×10−03 14.3 59(70.2) 25(29.8) 0.72(0.49–1.04) 8.3×10−02 12.9 114(67.5) 55(32.5) 0.63(0.49–0.81) 4.1×10−04 14.1

miR-145 <0.62 77(91.7) 7(8.3) 1(reference) 8.2 73(90.1) 8(9.9) 1(reference) 9.6 150(90.9) 15(9.1) 1(reference) 8.8
>0.62 54(65.1) 29(34.9) 0.62(0.42–0.92) 1.7×10−02 15.7 67(72.0) 26(28.0) 0.70(0.49–0.99) 4.3×10−02 12.4 121(68.8) 55(31.3) 0.64(0.49–0.82) 4.4×10−04 12.7

miR-92a <0.63 77(88.5) 10(11.5) 1(reference) 8.6 73(91.3) 7(8.8) 1(reference) 8.9 150(89.8) 17(10.2) 1(reference) 8.7
>0.63 59(67.8) 28(32.2) 0.70(0.48–1.04) 7.6×10−02 14.1 70(72.9) 26(27.1) 0.66(0.47–0.92) 1.6×10−02 11.1 129(70.5) 54(29.5) 0.67(0.53–0.86) 1.6×10−03 12.4

let-7c <0.66 74(89.2) 9(10.8) 1(reference) 8.4 66(88.0) 9(12.0) 1(reference) 9.2 140(88.6) 18(11.4) 1(reference) 8.6
>0.66 56(68.3) 26(31.7) 0.65(0.44–0.94) 2.4×10−02 14.3 68(73.9) 24(26.1) 0.72(0.50–1.04) 7.7×10−02 11.6 124(71.3) 50(28.7) 0.68(0.53–0.87) 2.6×10−03 13.4

let-7b <0.60 78(90.7) 8(9.3) 1(reference) 8.6 89(92.7) 7(7.3) 1(reference) 9.3 167(91.8) 15(8.2) 1(reference) 9.0
>0.60 55(64.7) 30(35.3) 0.65(0.44–0.97) 3.5×10−02 11.3 53(67.1) 26(32.9) 0.67(0.46–0.98) 3.9×10−02 13.7 108(65.9) 56(34.2) 0.69(0.53–0.89) 4.5×10−03 12.7
a

Expression levels were calculated using the 2−ΔΔCt method. ΔCt was defined as the raw Ct value for a specific miRNA (or spike-in control miRNAs) in an individual sample minus the mean raw Ct value of this miRNA (or spike-in control miRNAs) in all the tested samples. ΔΔCt was defined as the difference between ΔCt of the specific miRNA and ΔCt of the spike-in control miRNAs.

b

Adjusted for age, sex, smoking status, clinical stage, and treatment regime